MDGL - Madrigal Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue----
Cost of Revenue----
Gross Profit----
Operating Expenses
Research Development25,38924,39015,9332,427.17
Selling General and Administrative15,2937,6726,590805.762
Non Recurring----
Total Operating Expenses40,68232,06222,5233,232.932
Operating Income or Loss-40,682-32,062-22,523-3,232.932
Income from Continuing Operations
Total Other Income/Expenses Net7,871908-3,865-3,611.931
Earnings Before Interest and Taxes-40,682-32,062-22,523-3,232.932
Interest Expense---1,213-3,611.931
Income Before Tax-32,811-31,154-26,388-6,844.863
Income Tax Expense----
Minority Interest----
Net Income From Continuing Ops-32,811-31,154-26,388-6,844.863
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-32,811-31,154-26,388-6,844.863
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-32,811-31,154-26,388-6,844.863